Keywords: exosomes; immunophenotype; inflamma-miRs; MDS biomarkers; miRNA; myelodysplastic syndromes EN exosomes immunophenotype inflamma-miRs MDS biomarkers miRNA myelodysplastic syndromes e4 e7 4 12/21/20 20210101 NES 210101 Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal disorders characterised by peripheral cytopenia, dysplasia in one or more myeloid cell lineage, bone marrow failure, and an increased risk of developing acute myeloid leukaemia (AML). Their average diameter was 103 ± 18 nm in MDS patients, 114 ± 29 nm in AML patients, 102 ± 10 nm in CMML patients, and 110 ± 11 nm in controls. *P <= 0-05 **P <= 0-01. gl The inflamma-miRs identified in MDS patients appear to be involved in disease development and progression and could be reliable biomarkers of MDS development and predict the outcomes of individual patients. [Extracted from the article]